Can-Fite BioPharma Ltd. CANF
Set alert
At close · Nov 2
After hours · Nov 2, 4:47 PM ET
- YTD
- -59.25%
- 1 year
- -80.60%
- Open
- 1.62
- Prev close
- 1.62
- Mkt cap
- 4.94M
- Vol
- 33.37K
- Avg vol
- 376.38K
- EPS
- -13.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.61
- High
- 1.66
- Forward P/E
- -2.00
- Beta
- 0.57
- Short ratio
- 1.96
- Inst. own
- 8.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.08
- 200-d avg
- 2.37
- 1y target
- 14.00
1Y chart
Events in this range
- Jan 5, 2026Split: 1 for 20
Signals (45)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 2026 | 8 hours ago |
| MACD: Sell Signal | Oct 28, 2026 | 5 days ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| RSI: Overbought | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| RSI: Overbought | Mar 4, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| SMA: Bearish | Feb 24, 2026 | 8 months ago |
| SMA: Bullish | Feb 20, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 10 months ago |
| RSI: Oversold | Dec 29, 2025 | 10 months ago |
| RSI: Oversold | Dec 22, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 19, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 18, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 14, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 10, 2025 | 11 months ago |
Key statistics
- Market cap
- 8.90M
- Enterprise value
- 2.47B
- Trailing P/E
- 0.00
- Forward P/E
- -2.00
- PEG ratio
- 0.00
- Price / sales
- 13.34
- Price / book
- 1460.00
- EPS (TTM)
- -2.60
- Beta
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 667.00K
- Revenue growth
- -19.40%
- Free cash flow
- -4.55M
- Total cash
- 4.73M
- Total debt
- 57.00K
- Return on equity
- -157.62%
- Shares outstanding
- 6.10M
- Short % of float
- 2.51%
- 50-day average
- 2.08
- 200-day average
- 2.37
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 14.00
- Target (high)
- 18.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 17, 2024 | EF Hutton | init | — | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 2, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- canfite.com
News
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Can-Fite BioPharma Says EAPO Issues Notification Of Readiness To Grant Patent Covering Use Of Piclidenoson For Treatment Of Diseases Associated With OCRL Deficiency
- Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
- Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes
- Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
- Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
- Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY
- Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Your note
Sign in to keep a note on CANF — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 42.17% | 650,000 | 949.00K | Sep 29, 2024 |
| Morgan Stanley | 3.29% | 50,660 | 73.96K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 1.92% | 29,570 | 43.17K | Sep 29, 2024 |
| Rhumbline Advisers | 1.10% | 16,945 | 24.74K | Sep 29, 2024 |
| Fifth Third Bancorp | 0.19% | 3,000 | 4.38K | Sep 29, 2024 |
| Wells Fargo & Company | 0.16% | 2,500 | 3.65K | Sep 29, 2024 |